Given that PARPis can slow AML cell growth and affect the differentiation of AML1-ETO- and PML-RARA-transformed mouse cells, we postulated that olaparib may repress CML progression in vivo. Here, RARA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.